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ABSTRACT
Study queStion
What are the benefits and harms of second generation 
antidepressants and cognitive behavioral therapies 
(CBTs) in the initial treatment of a current episode of 
major depressive disorder in adults?
MethodS
This was a systematic review including qualitative 
assessment and meta-analyses using random and 
fixed effects models. Medline, Embase, the Cochrane 
Library, the Allied and Complementary Medicine 
Database, PsycINFO, and the Cumulative Index to 
Nursing and Allied Health Literature were searched 
from January1990 through January 2015. The 11 
randomized controlled trials included compared a 
second generation antidepressant CBT. Ten trials 
compared antidepressant monotherapy with CBT 
alone; three compared antidepressant monotherapy 
with antidepressant plus CBT.
SuMMary anSwer and liMitationS
Meta-analyses found no statistically significant 
difference in effectiveness between second generation 
antidepressants and CBT for response (risk ratio 0.91, 
0.77 to 1.07), remission (0.98, 0.73 to 1.32), or change 
in 17 item Hamilton Rating Scale for Depression score 
(weighted mean difference, −0.38, −2.87 to 2.10). 
Similarly, no significant differences were found in rates 
of overall study discontinuation (risk ratio 0.90, 0.49 
to 1.65) or discontinuation attributable to lack of 
efficacy (0.40, 0.05 to 2.91). Although more patients 
treated with a second generation antidepressant than 
receiving CBT withdrew from studies because of 
adverse events, the difference was not statistically 
significant (risk ratio 3.29, 0.42 to 25.72). No 
conclusions could be drawn about other outcomes 
because of lack of evidence. Results should be 
interpreted cautiously given the low strength of 
evidence for most outcomes. The scope of this review 
was limited to trials that enrolled adult patients with 
major depressive disorder and compared a second 
generation antidepressant with CBT, and many of the 
included trials had methodological shortcomings that 
may limit confidence in some of the findings.
what thiS Study addS 
Second generation antidepressants and CBT have 
evidence bases of benefits and harms in major 
depressive disorder. Available evidence suggests no 
difference in treatment effects of second generation 
antidepressants and CBT, either alone or in 
combination, although small numbers may preclude 
detection of small but clinically meaningful 
differences.
Funding, CoMpeting intereStS, data Sharing
This project was funded under contract from the Agency 
for Healthcare Research and Quality by the RTI-UNC 
Evidence-based Practice Center. Detailed methods and 
additional information are available in the full report, 
available at http://effectivehealthcare.ahrq.gov/.
Introduction
Major depressive disorder is the most prevalent and dis-
abling form of depression, affecting more than 32 mil-
lion Americans.1  In any given year, nearly 7% of the 
American adult population has an episode of major 
depressive disorder, but only about half of these people 
seek care.1  For patients who do obtain care, only 20% 
receive adequate treatment.1  Based on available evi-
dence based guidelines, this would include either drug 
therapy (at least two months of an appropriate drug for 
major depressive disorder plus more than four visits to 
any type of physician) or psychotherapy (at least eight 
visits with any healthcare professional lasting an aver-
age of at least 30 minutes).2-4
Treatment for major depressive disorder is often 
started in a primary care setting,5  and patients gener-
ally receive drugs as the standard treatment.6  Of the 
available antidepressants, second generation antide-
pressants are the most commonly prescribed agents.6 
These drugs include selective serotonin reuptake 
 inhibitors, serotonin and norepinephrine reuptake 
WhAT IS AlReAdy knoWn on ThIS TopIC
Second generation antidepressants and cognitive behavioral therapy have 
evidence bases of benefits and harms in major depressive disorder
However, primary care physicians require high quality evidence of the comparative 
effectiveness of the available treatments to select and manage the best options for 
their patients
WhAT ThIS STudy AddS
The available evidence suggests no difference in treatment effects of second 
generation antidepressants and cognitive behavioral therapies, either alone or in 
combination, in major depressive disorder
Given that patients may have personal preferences for one first line treatment over 
the other, both treatments should be made accessible, either alone or in 
combination, to primary care patients with major depressive disorder
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inhibitors, and other drugs with related mechanisms of 
action that target specific neurotransmitters. Although 
these drugs have different mechanisms of action, evi-
dence suggests that no substantial differences in bene-
fits exist among them as a class.7
Although drug therapy is the treatment most fre-
quently offered to depressed primary care patients, data 
from studies of antidepressant drugs show that approx-
imately 20% of patients do not fill their prescriptions. 
Moreover, even if they start a course of treatment, they 
may discontinue early before receiving an adequate 
course.8  One reason for lack of adherence to second 
generation antidepressants is the frequency and sever-
ity of side effects. More than 60% of patients have at 
least one adverse effect during treatment with a second 
generation antidepressant. Although most adverse 
effects are minor (for example, constipation, diarrhea, 
and dizziness), they frequently lead to discontinuation 
of treatment.9
Patients’ preferences for starting or switching treat-
ment may also play a key role in acceptance and contin-
uation of treatment for major depressive disorder. Some 
research suggests that patients might prefer treatment 
with psychotherapy over drugs.10-14  Reasons for prefer-
ring psychotherapy over drugs include concerns about 
side effects and perceived “addictiveness” of drugs.12 15-18 
In addition, women and ethnic minorities may be more 
likely to prefer psychotherapies over drugs.12 13 19 20 
Regardless of which treatment patients prefer, some 
evidence suggests that patients who receive their treat-
ment of choice fare better than those whose treatment is 
incongruous with their preferences.11 21
In general, psychotherapeutic interventions aim to 
help patients to identify how past and present factors 
may contribute to their depression and to teach them 
how to deal effectively with them.22-25 Cognitive behav-
ioral therapy is based on a combination of basic behav-
ioral and cognitive principles. Briefly, it helps patients 
to understand and examine how their thoughts, moods, 
and behaviors interact in a way that can result in or 
worsen depression. Patients are taught how to replace 
dysfunctional thoughts and behaviors with more adap-
tive ones, which can reduce distress and improve mood.
Given the range of available treatments for patients 
with major depressive disorder, each with its own evi-
dence base of benefits and harms, primary care physi-
cians require high quality evidence of the comparative 
effectiveness of the available treatments to select and 
manage the best options for their patients. This paper 
focuses on the comparative benefits of second genera-
tion antidepressants and cognitive behavioral thera-
pies as an initial treatment of a current episode of 
major depressive disorder in adults. Our results come 
from a larger comparative effectiveness review of ben-
efits and harms of second generation antidepressants, 
psychotherapies (including psychotherapies other 
than cognitive behavioral therapy), complementary 
and alternative medicine treatments, and exercise 
 interventions for major depressive disorder funded by 
the US Agency for Healthcare Research and Quality.26
Methods
Detailed methods are available in the full report.26 The 
full search strategy is available in web appendix A. In 
brief, we searched Medline, Embase, the Cochrane 
Library, the Allied and Complementary Medicine Data-
base, PsycINFO, and the Cumulative Index to Nursing 
and Allied Health Literature for randomized and 
non-randomized controlled trials published from Janu-
ary1990 through January 2015. For drugs, we searched 
for individual generic drug names and broader second 
generation antidepressant related terms; for cognitive 
behavioral therapy studies, we used the terms “psycho-
therapy,” “cognitive therapy,” and “cognitive behav-
ioral therapy” in titles or abstracts. To detect 
unpublished studies, we searched ClinicalTrials.gov, 
the World Health Organization’s International Clinical 
Trials Registry Platform, Drugs@FDA, the European 
Medicines Agency, the National Institute of Mental 
Health website, the American Psychological Associa-
tion website, Scopus, the Conference Proceedings Cita-
tion Index, and reference lists of pertinent reviews and 
included trials.
Table 1  contains the eligibility criteria that we applied 
to search results. Briefly, we included studies that com-
pared a second generation antidepressant with cogni-
tive behavioral therapy for the initial treatment of a 
current episode of major depressive disorder in adults. 
Cognitive behavioral therapy is the umbrella “class” 
with which we compared second generation antide-
pressants. However, we recognize the challenge in orga-
nizing and categorizing psychological interventions in 
systematic reviews. In an effort to enhance the consis-
tency of categorization of psychotherapies in this 
table 1 | inclusion criteria for studies comparing second generation antidepressant with cognitive behavioral therapy
parameter Criteria
Population Adult (18 years or older) outpatients with major depressive disorder during initial treatment attempt for current episode 
Interventions Second generation antidepressants approved for treatment of major depressive disorder by the US Food and Drug Administration: bupropion, citalopram, 
desvenlafaxine, duloxetine, fluoxetine, escitalopram, fluvoxamine, levomilnacipran, mirtazapine, nefazodone, paroxetine, sertraline, trazodone, venlafaxine, 
vilazodone, vortioxetine
Cognitive behavioral therapies as classified by Cochrane Collaborative Depression, Anxiety and Neurosis Group’s framework27
Outcomes Benefits: response, remission, speed of response, speed of remission, relapse, quality of life, functional capacity, suicidal ideas or behaviors, hospital 
admission
Harms: overall adverse events, withdrawals because of adverse events, serious adverse events, specific adverse events (including hyponatremia, seizures, 
suicidal ideas or behaviors, hepatotoxicity, weight gain, gastrointestinal symptoms, sexual side effects), withdrawals because of specific adverse events
Study designs Benefits: randomized controlled trials, systematic reviews, and meta-analyses
In addition for harms: non-randomized controlled trials, prospective controlled cohort studies, retrospective controlled cohort studies, case-control studies, 
all with minimum sample size of 500 participants
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review and our ability to compare our findings with 
those of other large reviews, we have used the Cochrane 
Collaborative Depression, Anxiety and Neurosis 
Group’s framework for categorizing psychological inter-
ventions.27 In addition to the umbrella term cognitive 
behavioral therapy, the framework’s cognitive behav-
ioral therapy category includes problem solving ther-
apy, rational emotive therapy, reality therapy, 
restructuring, role play, schemas, self control, and 
stress management. If the authors of an included trial 
specified the particular form of the behavioral interven-
tion, we mention it; if they did not, we use the term cog-
nitive behavioral therapy.
Two trained team members independently reviewed 
all abstracts and full text articles against predefined 
inclusion/exclusion criteria. Investigators resolved dis-
agreements about inclusion or exclusion by consensus 
or by involving a third reviewer. We designed, pilot 
tested, and used a structured data abstraction form to 
ensure consistency of data abstraction. Trained review-
ers initially abstracted data from each study; a senior 
reviewer evaluated the completeness and accuracy of 
the data abstraction.
We rated the risk of bias for each relevant outcome of 
a study as low, moderate, or high. To determine risk of 
bias in a standardized way, we used the Cochrane Risk 
of Bias tool to appraise randomized controlled trials.28 
Two independent reviewers assigned ratings for risk of 
bias. They resolved any disagreements by discussion 
and consensus or by consulting a third member of the 
team. We included all eligible studies in this review 
regardless of risk of bias, but we used studies rated as at 
high risk of bias only in sensitivity analyses. Risk of bias 
assessments are shown in appendix B.
We graded the strength of evidence on the basis of 
guidance established by the US Agency for Healthcare 
Research and Quality for the Evidence-based Practice 
Center program.29 This approach, which is based largely 
on the approach developed by the Grading of Recom-
mendations Assessment, Development and Evaluation 
(GRADE) Working Group, incorporates five domains: 
study limitations, consistency, directness, precision, 
and reporting bias. Grades (high, moderate, low, insuf-
ficient) reflect the confidence we had about the evi-
dence for a specific outcome on the comparative 
benefits and harms of the interventions.
Evidence suggests that no substantial differences in 
benefits exist among the different types of second gen-
eration antidepressants7; therefore, in all meta-analy-
ses we compared second generation antidepressants as 
a class with cognitive behavioral therapies. When we 
did meta-analyses, we assessed statistical heterogene-
ity in effects between studies by calculating the χ2 sta-
tistic and Cochran’s q. We used the I2 statistic (the 
proportion of variation in study estimates attributable 
to heterogeneity) to estimate the magnitude of hetero-
geneity. We examined potential sources of heterogene-
ity by using sensitivity and subgroup analyses.
For all analyses, we used random effects and fixed 
effects models to estimate comparative effects. We used 
DerSimonian and Laird models for random effects anal-
yses. For studies with attrition, we used a “worst case” 
assumption that non-completers failed to respond or 
remit. We used funnel plots to assess publication bias, 
but given the small number of studies in our meta-anal-
yses, these tests have low sensitivity to detect publica-
tion bias. We used Comprehensive Meta-analysis, 
version 3.2 (Biostat; Englewood, NJ, USA) for all 
meta-analyses.
patient involvement
A representative of the National (US) Board of Directors 
of the National Alliance on Mental Illness participated 
in the refinement of the research topic and the develop-
ment of the preliminary research questions and review 
criteria. The research question and a draft version of the 
report were posted online for input from all members of 
the public, including patients and their advocates. Dis-
semination of results will include a translation of the 
results into short, easy to read summaries and tools that 
can be used by patients, caregivers, and others who use 
healthcare services.
Results
literature searches and evidence base
Our searches for the full report identified 7813 citations, 
of which we included 11 primary randomized controlled 
trials (reported in 14 articles) that compared a second 
generation antidepressant with cognitive behavioral 
therapy and provided data relevant to this paper 
(fig 1 ).30-43 Those studies provided information on 1511 
patients with major depressive disorder.
Two trials were conducted in primary care set-
tings38 39 ; the remainder took place in outpatient mental 
healthcare locations. Four trials took place solely in the 
Additional records identied
through other sources (n=16)
Records identied through database
searching (aer duplicates removed) (n=7797)
Titles/abstracts screened (n=7813)
Full text articles assessed for eligibility (n=445)
Trials included in full review evidence sythesis (n=44; 55 articles)
Trials included in SGA v CBT evidence sythesis (n=11; 14 articles)
Records excluded (n=7368)
Records excluded from this paper
owing to comparison between SGA




  Ineligible publication type (n=59)
  Ineligible population(s) (n=84)
  Ineligible or no intervention(s) (n=34)
  Ineligible study design (n=56)
  Ineligible or no comparison(s) (n=131)
  Ineligible outcome(s) (n=10)
  Not relevant to full review (n=5)
  Abstract only (n=11)
Fig 1 | priSMa diagram for second generation antidepressants versus cognitive behavioral 
therapy in treatment of major depressive disorders
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United States;30 35 37 38 other countries included Can-
ada,33 36 42  England,39  Germany,40  Iran,43  and Romania.32
Generally, patients were aged between 18 and 65 
years; most trials reported a mean age between 35 and 
45 years. In all trials, most patients were female. One 
trial enrolled only women.38 In the few trials that 
reported race or ethnicity, a quarter of patients were 
non-white. All trials reported mean baseline severity of 
depression of at least a moderate degree; most trials 
reported mean baseline scores on the 17 item Hamilton 
Rating Scale for Depression between 16 (moderate 
depression) and 23 (severe). The total daily dose of each 
second generation antidepressant drug was within the 
usual ranges prescribed for adults.
Table 2  describes the 11 included trials (14 publica-
tions) of a second generation antidepressant compared 
with cognitive behavioral therapy. Second generation 
antidepressants used in the trials were fluoxetine,32  flu-
voxamine,39  paroxetine,35-37 39  sertraline,36 40  venlafax-
ine,33 36 citalopram,43  and escitalopram.30  42  Because of 
the inherent heterogeneity in delivery of psychothera-
pies, even for those under the umbrella of cognitive 
behavioral therapy, we used the individual studies’ 
definitions of the cognitive therapies provided. Six tri-
als used cognitive behavioral therapy,30 33 36 38 40 42  four 
used the specific cognitive therapy modality,32 35 37 43  and 
one each used problem solving therapy and rational 
emotive therapy modalities.32 39  Trial counts exceed 11 
because one trial had both cognitive therapy and ratio-
nal emotive therapy arms.32  All but one trial compared 
second generation antidepressant monotherapy with 
cognitive behavioral therapy alone; Lam and colleagues 
compared second generation antidepressant monother-
apy with second generation antidepressant plus cogni-
tive behavioral therapy.42 Two trials included an 
additional comparison of second generation antide-
pressant monotherapy with a combination of second 
generation antidepressant and cognitive behavioral 
therapy.39 43 Treatment duration ranged from eight 
weeks to one year; some trials also reported follow-up 
results once patients were no longer receiving active 
treatments.
We present our findings first by treatment compari-
son (monotherapy comparisons followed by combina-
tion therapy comparisons). Within each comparison, 
we present the benefits followed by the harms. Table 3 
summarizes the findings and respective strength of evi-
dence ratings for all comparisons and outcomes.
Second generation antidepressant versus cognitive 
behavioral therapy: monotherapy comparisons
We did random effects meta-analyses of trials rated as 
at low or medium risk of bias for remission, response, 
and change in 17 item Hamilton Rating Scale for Depres-
sion score. We also did sensitivity analyses for those 
outcomes including additional trials rated as at high 
risk of bias.30 33 36
For remission, we included three trials (four compar-
isons) with a total of 432 patients.32 35 39 We analyzed 
results measured between 12 and 16 weeks. The three 
trials defined remission on the basis of a 17 item 
 Hamilton Rating Scale for Depression score of either 
less than 732  or less than or equal to 7.35 39 One trial also 
required a score less than or equal to 10 on the Beck 
Depression Inventory for remission.35 Patients treated 
with second generation antidepressants had numeri-
cally lower but not significantly different remission 
rates than patients receiving cognitive behavioral ther-
apy (40.7% v 47.9%; risk ratio 0.98, 95% confidence 
interval 0.73 to 1.32; fig 2 ; low strength of evidence). Our 
sensitivity analysis including three trials at high risk of 
bias yielded a similar, non-significant difference (risk 
ratio 1.08, 0.90 to 1.29).30 33 36
For response, we included results from 660 patients 
studied in five trials (six comparisons).32 35 37 39 40 We ana-
lyzed results measured between eight and 16 weeks. 
The five trials defined response as a 50% or greater 
reduction from baseline in 17 item Hamilton Rating 
Scale for Depression score. Treatment effects were sim-
ilar for second generation antidepressants and cogni-
tive behavioral therapies (44.2% v 45.5%; risk ratio 0.91, 
0.77 to 1.07; fig 3 ; moderate strength of evidence). The 
sensitivity analysis including three studies at high risk 
of bias yielded a similarly non-statistically significant 
difference in response between second generation anti-
depressants and cognitive behavioral therapies (risk 
ratio 1.02, 0.83 to 1.25).30 33 36
Our analysis of the two trials (three comparisons; 249 
patients)32  39  that reported change in 17 item Hamilton 
Rating Scale for Depression scores at eight weeks or lon-
ger found no statistically significant difference between 
second generation antidepressants and cognitive 
behavioral therapies (weighted mean difference −0.38, 
−2.87 to 2.10; fig 4 ). Adding the trials at high risk of bias 
to the model yielded no difference in comparative effec-
tiveness (−0.27, −2.44 to 1.90).33 40
Two trials, both rated as at medium risk of bias, 
reported response, remission, or change in 17 item 
Hamilton Rating Scale for Depression score at time 
points beyond 16 weeks. In one,32  patients receiving 
either rational emotive therapy or cognitive therapy 
reported higher rates of remission and response at six 
months than patients taking a second generation anti-
depressant, although neither difference was statisti-
cally significant. At six months, patients receiving 
rational emotive therapy or cognitive therapy reported 
significantly lower 17 item Hamilton Rating Scale for 
Depression scores than did the patients taking the sec-
ond generation antidepressant. In the trial that com-
pared second generation antidepressants with problem 
solving therapy,39 the rate of remission at one year was 
higher in the problem solving therapy arm, although 
rate of response at one year was higher in the second 
generation antidepressant arm. In that trial, patients’ 17 
item Hamilton Rating Scale for Depression scores con-
tinued to decline, with one year scores being lower in 
the problem solving therapy arm than the second gen-
eration antidepressant arm. Again, these differences 
failed to reach statistical significance.
With respect to other health outcomes, three trials 
reported relapse rates during off treatment fol-
low-up.32 35 36 45  Two trials defined relapse as symptom 
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levels meeting criteria for major depressive disorder; 
the third defined relapse as either a 17 item Hamilton 
Rating Scale for Depression score of 14 or greater or a 
psychiatric status rating of 5 or greater during the first 
year of follow-up.35  During the follow-up period of that 
trial,35 patients who had initially received cognitive 
therapy did not receive any treatment, and patients 
who had received second generation antidepressant 
were randomized to continue second generation anti-
depressant or switched to a placebo pill. 
In one trial at medium risk of bias,32  10.6% of patients 
treated with second generation antidepressant relapsed 
within six months, compared with 2.1% and 6.1% of 
patients treated with rational emotive therapy and cog-
nitive therapy, respectively (statistical significance not 
reported). In the other trial at medium risk of bias,35 45 
the rates of relapse within the first year of follow-up 
were 39% for previous cognitive therapy, 53% for 
patients who were in the second generation antidepres-
sant arm and continued to receive it during follow-up, 
and 59% for patients who received second generation 
antidepressants during the acute phase but were 
switched to placebo during follow-up. Previous cogni-
tive therapy was significantly different from previous 
second generation antidepressant switched to placebo 
(P=0.02). In the trial rated as at high risk of bias,36 47% 
of patients treated with a second generation antidepres-
sant who achieved remission and 39% of those treated 
with cognitive behavioral therapies who achieved 
remission relapsed within 18 months (P=0.40). 
Finally, one trial at medium risk of bias reported 
recurrence during the second year of follow-up, defined 
as either a 17 item Hamilton Rating Scale for Depression 
table 3 | Strength of evidence and summary of findings




Second generation antidepressant versus cognitive behavioral therapy monotherapy comparisons
Remission Low Results from direct comparisons in three trials indicate that no differences in remission exist between second generation 
antidepressants and cognitive behavioral therapy monotherapy (risk ratio 0.98, 95% CI 0.73 to 1.32)
Response Moderate Results from direct comparisons in five trials indicate that no substantial differences in response exist between second 
generation antidepressants and cognitive behavioral therapy monotherapy (risk ratio 0.91, 0.77 to 1.07)
Functional capacity Low Results from one trial indicate that no substantial differences in functional capacity exist between second generation 
antidepressants and cognitive behavioral therapy monotherapy
Overall risk of adverse events Insufficient On the basis of one trial with few events, the evidence is insufficient to draw conclusions
Overall discontinuation of 
treatment 
Moderate Results from direct comparisons in four trials indicate that no significant differences exist in overall discontinuation 
between patients treated with second generation antidepressants and those treated with cognitive behavioral therapy (risk 
ratio 1.00, 0.55 to 1.81)
Discontinuation of treatment 
because of adverse events
Low Results from direct comparisons in three trials indicate that patients treated with second generation antidepressants have a 
numerically but not statistically significant higher rate of discontinuation because of adverse events than those treated with 
cognitive behavioral therapy (risk ratio 2.54, 0.39 to 16.47)
Second generation antidepressant versus combination of second generation antidepressant and cognitive behavioral therapy
Remission Low Results from direct comparisons in two trials indicate that no substantial differences in remission exist between second 
generation antidepressants and second generation antidepressants combined with cognitive behavioral therapy (risk ratio 
1.06, 0.82 to 1.38)
Response Low Results from direct comparisons in two trials indicate that no substantial differences in response exist between second 
generation antidepressants and second generation antidepressants combined with cognitive behavioral therapy (risk ratio 
1.03, 0.85 to 1.26)
Functional capacity Low Results from one trial indicate that the combination of second generation antidepressant with cognitive behavioral therapy 
results in statistically significantly greater improvement on 3/4 work functioning measures than second generation 
antidepressant alone
Overall discontinuation of 
treatment
Low Results from direct comparisons in two head to head trials indicate that no significant differences exist in overall 
discontinuation between patients treated with second generation antidepressants and those treated with cognitive 
behavioral therapy (risk ratio 0.77, 0.37 to 1.60)
Discontinuation of treatment 
because of adverse events
Low Results from direct comparisons in two head to head trials indicate that no significant differences exist in discontinuation 
because of adverse events between patients treated with second generation antidepressants and those treated with 
cognitive behavioral therapy (risk ratio 2.93, 0.72 to 11.91)
*Grades (high, moderate, low, or insufficient) are based on methods guidance for US Agency for Healthcare Research and Quality for the Evidence-based Practice Center program.44
  David 2008a
  David 2008b
  DeRubeis 2005
  Dimidjian 2006a
  Hegerl 2010
  Mynors-Wallis 2000
Overall
Random eects meta-analysis: I2=0%
0.89 (0.62 to 1.29)
0.94 (0.65 to 1.35)
1.15 (0.82 to 1.62)
0.74 (0.53 to 1.04)
0.77 (0.39 to 1.50)
0.81 (0.28 to 2.37)
0.91 (0.77 to 1.07)
0.5 1 2
Author
Favours CBT Favours SGA


















Fig 3 | Second generation antidepressants (Sga) versus cognitive behavioral therapy 
(CBt): response
  David 2008a
  David 2008b
  Dimidjian 2006a
  Mynors-Wallis 2000
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Fig 2 | Second generation antidepressants (Sga) versus cognitive behavioral therapy 
(CBt): remission
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score of 14 or greater or a psychiatric status rating of 5 or 
greater among those who did not relapse during year 1 
of follow-up.35  The rates of recurrence during year 2 
were 24% for previous cognitive therapy and 52% for 
patients who were taking second generation antide-
pressants during the acute phase (P=0.06). Owing 
largely to small numbers of patients in each group (17 in 
each group), the difference was not statistically signifi-
cant. The single trial (also at medium risk of bias) that 
reported measures of functional capacity used the 
Social Adjustment Scale39; second generation antide-
pressant and problem solving therapy did not differ at 
end of treatment or at 40 week off-treatment follow-up 
(P>0.05 at both times).
With regard to adverse events, reporting was gener-
ally poor, particularly for serious adverse events and 
specific adverse events. As a result, we analyzed rates of 
discontinuation as proxies for adverse events. Overall 
discontinuation from the four studies at medium risk of 
bias did not differ significantly between second genera-
tion antidepressants and cognitive behavioral therapies 
(risk ratio 1.00, 0.55 to 1.81; I2=47%; moderate strength 
of evidence).32 35 37 39  Adding three studies at high risk of 
bias did not change the result (risk ratio 0.92, 0.69 to 
1.23).30 33 40  More patients treated with a second genera-
tion antidepressant than receiving cognitive behavioral 
therapy withdrew from studies owing to adverse events 
(risk ratio 2.54, 0.39 to 16.47; three studies35 37 39; I2=62%), 
but the difference was not statistically significant (low 
strength of evidence). Again, including a trial at high 
risk of bias did not affect the results (risk ratio 2.97, 0.69 
to 12.81).40  Finally, second generation antidepressants 
and cognitive behavioral therapies did not differ signifi-
cantly in terms of dropouts attributed to lack of efficacy 
in the main analysis (risk ratio 0.36, 0.06 to 2.21; three 
studies35 37 39; I2=51%). 
Second generation antidepressant versus cognitive 
behavioral therapy: combination comparisons
The three trials that compared second generation anti-
depressant monotherapy with a combination of second 
generation antidepressant and cognitive behavioral 
therapy reported no statistically significant between 
group differences in rates of either remission or 
response (low strength of evidence).39 42 43  All reported 
change in depression scale score between baseline and 
endpoint; one reported a significant between group dif-
ference—namely, a smaller decrease in scores on the 
Montgomery-Åsberg Depression Rating Scale for 
patients taking second generation antidepressant alone 
than for patients treated with second generation antide-
pressant plus cognitive therapy.43  That trial, however, 
was rated as at high risk of bias, whereas the other two 
were rated as at low42  and medium39 risk of bias. 
The trial that compared second generation antide-
pressant alone with second generation antidepressant 
plus telephone cognitive behavioral therapy measured 
several work related outcomes.42  Patients receiving the 
combination of second generation antidepressant and 
telephone cognitive behavioral therapy reported 
greater improvement on three of four work functioning 
measures. The authors found no between group differ-
ences in reduction of hours of work missed, although 
both groups reported a decrease at the end of treat-
ment. In the trial that compared second generation 
antidepressant alone with the combination of second 
generation antidepressant and problem solving ther-
apy, groups did not differ in the Social Adjustment 
Scale at end of treatment or at 40 week off-treatment 
follow-up.39
Two of the three trials reported adverse events.39 42 In 
the trial rated as at low risk of bias, more patients with-
drew for any reason from the combination arm than 
from the second generation antidepressant alone arm 
(23% v 13%; significance not reported).42 However, 
slightly more patients withdrew owing to adverse 
events from the second generation antidepressant 
alone arm (6%) compared with the combination arm 
(4%). In the other trial, rated as at medium risk of bias, 
discontinuation rates were similar between the second 
generation antidepressant alone and combination arms 
(17% in each arm).39 Eleven per cent and 6% of patients 
in the combination and second generation antidepres-
sant arms, respectively, withdrew because of adverse 
events. No patients in either arm withdrew because of 
lack of treatment efficacy. The low number events in 
each of these outcomes results in a low strength of evi-
dence rating. 
discussion
For second generation antidepressants compared with 
cognitive behavioral therapies, the available evidence 
based on 11 randomized controlled trials with 1511 
patients suggests no difference in treatment effects of 
second generation antidepressants and cognitive 
behavioral therapies, either alone or in combination, 
although our conclusions are tempered by small num-
bers and mostly low strength of evidence. Relative risks 
of remission and response were nearly identical for 
monotherapy comparisons (0.98 and 0.91, respectively) 
and for second generation antidepressant alone versus 
combination (1.06 and 1.03, respectively). Adverse event 
outcomes were also clinically and statistically similar 
for all comparisons. 
Comparison with other studies and guidelines
Our findings are relatively consistent with similar 
meta-analyses by Cuijpers and colleagues that com-
pared second generation antidepressants with 
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 cognitive behavioral therapy.25 46-48 In addition to con-
taining several more recent studies, our analyses have 
some key methodological differences that make them 
more relevant for the primary care population. 
Cuijpers and colleagues did meta-analyses of second 
generation antidepressants compared with any psy-
chotherapy and of cognitive behavioral therapy com-
pared with any drug, but they did not report results 
from a specific comparison between second genera-
tion antidepressant and cognitive behavioral therapy 
for adults with major depressive disorder. They found 
that only selective serotonin reuptake inhibitors, 
rather than second generation antidepressants as a 
class, were more effective than any type of psychother-
apy in treating patients with major depressive disor-
der; however, the effect was small and potentially 
clinically insignificant. Furthermore, they did not 
require the use of evidence based psychotherapy (for 
example, non-directive supportive counseling was eli-
gible for their analyses), they did not limit studies to 
those in which patients had not already failed a previ-
ous antidepressant treatment (who would be more 
likely to be seen in primary care). Finally, their analy-
ses did not report on comparative harms, which we 
have done in this report.
Spielmans and colleagues found that bona fide cog-
nitive behavioral therapy (based on their included 
studies’ descriptions of therapist training, thera-
pist-client relationship, and therapy components) 
resulted in better outcomes that second generation 
antidepressant, but the effect sizes were small and het-
erogeneity was high.25 Although we considered treat-
ment fidelity in our risk of bias assessment, we did not 
attempt to determine whether the cognitive behavioral 
therapy offered in the included trials was “bona fide.” 
Because primary care clinicians are unlikely to have 
the information necessary to determine whether the 
cognitive behavioral therapy to which they refer 
patients is bona fide, our results may be more relevant 
to primary care providers. 
Our results are also consistent with the recommenda-
tions of the American Psychiatric Association,3  the US 
Department of Veterans Affairs/Department of 
Defense,49  and the UK National Institute for Health and 
Care Excellence.50 Those groups consider both drugs 
and psychotherapy to be appropriate individual initial 
treatments for patients with mild to moderate major 
depressive disorder. Furthermore, they state that drugs 
plus psychotherapy may be a useful initial treatment for 
patients with a current episode of moderate to severe 
major depressive disorder and for those with major 
depressive disorder and coexisting conditions. 
limitations
This review, and the evidence that informed it, does 
have limitations. The scope of this review was limited 
to trials that enrolled adult patients with major depres-
sive disorder and compared a second generation anti-
depressant with cognitive behavioral therapy (alone or 
in combination with a second generation antidepres-
sant). We did not attempt to review the literature on 
 interventions for major depressive disorder in children 
or for patients with subthreshold depression, dysthy-
mia, or perinatal depression. The included trials 
enrolled mostly patients with moderate to severe major 
depressive disorder; therefore, results may not be 
applicable to patients with milder major depressive 
disorder. Most trials excluded patients with medical 
comorbidities or suicidal ideation; few trials included 
elderly patients. We found insufficient evidence to con-
firm or refute whether treatments are more or less effi-
cacious for various subgroups (patients characterized 
by sex, race, or ethnicity or those with coexisting psy-
chiatric conditions).
Many of the included trials, even those rated as at 
medium risk of bias, had methodological shortcomings 
that may limit confidence in some of our findings. Sev-
eral studies reported very high attrition, although rates 
were usually similar between treatment groups. Our 
“worst case” assumption of withdrawals as failures to 
respond or remit should alleviate some of that concern. 
Most of the included trials provided data only for acute 
phase treatment; information to help providers to man-
age ongoing depression or prevent relapse and recur-
rence is lacking.
Although studies of psychotherapy contain some 
inherent heterogeneity of the content and delivery, the 
included trials used treatment manuals with prescribed 
goals and techniques to minimize variability between 
therapists. The type, training, and experience of the cli-
nicians who render these various interventions were 
also quite diverse. Unlike the case with second genera-
tion antidepressants, which are broadly equivalent and 
have standardized dosing, the cumulative effect of the 
various sources of heterogeneity within and across psy-
chological interventions may limit the applicability of 
our findings. Clinician type, training, experience, and 
degree of treatment fidelity are likely to be even less 
consistent in routine clinical practice than in the trials 
in this review. Along with availability of psychothera-
pists, these are important factors for clinicians to con-
sider when recommending psychological treatment and 
interventions. 
Finally, comparative effectiveness at a group level did 
not detect a difference between second generation anti-
depressants and cognitive behavioral therapies, but 
how best to tailor this information to an individual 
patient is still not clear, especially given the low 
strength of evidence for most of the included outcomes. 
Preliminary evidence suggests that biomarkers may 
have a role in predicting response to cognitive behav-
ioral therapy compared with second generation antide-
pressants, but these findings have yet to be replicated or 
implemented in clinical practice.30 Analyses of individ-
ual patient level data are best suited to answer that 
question and should be done in the future. Although we 
searched for unpublished literature, publication bias 
and selective outcome reporting may still be potential 
limiting factors. Finally, because we did not compare 
active treatment with placebo or no treatment, we can-
not rule out the possibility that cognitive behavioral 
therapy and second generation antidepressants may be 
the bmj | BMJ   2015;101hh2019 | doi1 02.00;h/bmj.hh2019
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similarly ineffective. However, because evidence of 
 benefit from both treatments exists, a provider would 
be unlikely recommend no treatment instead.
Conclusions and policy implications
In clinical decision making, providers should consider 
not only the efficacy of second generation antidepres-
sants and cognitive behavioral therapy interventions 
but also patients’ preferences about potential adverse 
events, the costs and availability of each treatment, and 
expected treatment effects. Currently, the biggest bar-
rier to offering psychotherapy either alone or in combi-
nation with drugs may be how well patients can gain 
access to such mental healthcare clinicians. Given that 
the benefits of second generation antidepressants and 
cognitive behavioral therapy do not seem to differ sig-
nificantly in treating major depressive disorder and that 
primary care patients may have personal preferences 
for one first line treatment over the other, both treat-
ments should be made accessible, either alone or in 
combination, to primary care patients with major 
depressive disorder.8
Having access to psychotherapeutic interventions in 
the primary care setting might improve treatment out-
comes for patients with major depressive disorder. It 
has the potential to improve use of psychiatric consul-
tations and therapy and to enhance coordination of 
care between primary care clinicians and mental 
health professionals. It may also have additional 
downstream effects of reducing the stigma associated 
with mental illness in general, empowering patients to 
tackle the symptoms and problems associated not only 
with depression but also with other mental health 
related concerns and encouraging them to seek and 
maintain treatment more quickly at an earlier stage of 
their illness.
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